INT136181

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 2.94
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (BCR) signal transduction (BCR) plasma membrane (BCR)
kinase activity (BCR)
Anatomy Link Frequency
B-cell 1
platelet 1
BCR (Homo sapiens)
Pain Link Frequency Relevance Heat
palliative 4 44.36 Quite Low
Pain 8 31.52 Quite Low
headache 6 25.00 Low Low
corticosteroid 4 20.52 Low Low
visual analogue scale 4 5.00 Very Low Very Low Very Low
cva 4 5.00 Very Low Very Low Very Low
aspirin 4 5.00 Very Low Very Low Very Low
Paresthesia 4 5.00 Very Low Very Low Very Low
Antihistamine 3 5.00 Very Low Very Low Very Low
carpal tunnel syndrome 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Myeloid Leukemia 20 99.68 Very High Very High Very High
Philadelphia Chromosome 3 96.84 Very High Very High Very High
Autoimmune Disease 16 95.68 Very High Very High Very High
Myeloproliferative Disorder 32 95.64 Very High Very High Very High
Leukemia 9 95.28 Very High Very High Very High
Lymphatic System Cancer 20 82.00 Quite High
Chronic Myelomonocytic Leukemia 15 80.92 Quite High
Myelofibrosis 28 80.68 Quite High
Systemic Lupus Erythematosus 14 80.16 Quite High
Skin Cancer 5 75.00 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Imatinib mesylate (IM), is a selective and competitive inhibitor of tyrosine kinases, including BCR-ABL, ABL, KIT, and the platelet-derived growth factor receptors (PDGF-R).
Negative_regulation (inhibitor) of BCR in platelet
1) Confidence 0.42 Published 2003 Journal J. Exp. Clin. Cancer Res. Section Abstract Doc Link 16767900 Disease Relevance 0.64 Pain Relevance 0
Nilotinib (Tasigna; Novartis Pharmaceuticals) is a second-generation BCR-ABL tyrosine kinase inhibitor newly approved for the treatment of imatinib-resistant or imatinib-intolerant Philadelphia chromosome positive (Ph+) chronic myeloid leukemia in chronic phase or accelerated phase.
Negative_regulation (inhibitor) of BCR associated with leukemia and philadelphia chromosome
2) Confidence 0.42 Published 2010 Journal J Clin Pharmacol Section Abstract Doc Link 19948946 Disease Relevance 0.19 Pain Relevance 0
Imatinib mesylate is successful in the therapy of CML because of the inhibition of the BCR-ABL kinase (Druker et al 1996).
Negative_regulation (inhibition) of BCR associated with myeloid leukemia
3) Confidence 0.42 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721304 Disease Relevance 1.38 Pain Relevance 0
Indeed, antagonistic antibodies to CD22 could provoke downregulation of the BCR (by SHP-1 [Src homology phosphatase-1] recruitment) and inhibiting T- and B-cell crosstalk by downregulation of the CD40 pathway [15,18,19].
Negative_regulation (downregulation) of BCR in B-cell
4) Confidence 0.33 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1779377 Disease Relevance 0.25 Pain Relevance 0
Its known mechanism of action is believed to be the downregulation of the BCR, with mechanisms of action differing from rituximab (by CD22 phosphorylation and BCR effects via immobilised Ig crosslinking) [18,21].
Negative_regulation (downregulation) of BCR
5) Confidence 0.33 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1779377 Disease Relevance 0.47 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox